IN8bio Phase 1 INB-100 shows 100% durable CR at 1 year in leukemia patients

IN8BIO, INC.

100% of evaluable leukemia patients (n=10) remain in durable CR at 1 year as of May 31, 2024.
First allogeneic cellular therapy to show in vivo gamma-delta T cell expansion/persistence at 365 days.
Favorable safety: no DLTs, CRS, neurotoxicity, or ICANS observed.
Two patients relapse-free >3.5 years; third nearing 3 years post-transplant.
Trial expanded at Dose Level 2; FDA Type B meeting planned this summer for potential registrational path.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.